These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19403738)

  • 1. Promoting science over serendipity in prescribing anti-TNF therapy.
    Chee MM; Alcorn N; Paterson K; Madhok R
    Rheumatology (Oxford); 2009 Aug; 48(8):865-6. PubMed ID: 19403738
    [No Abstract]   [Full Text] [Related]  

  • 2. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 3. Rheumatoid Arthritis - Anti-TNF.
    Chaabo K; Kirkham B
    Int Immunopharmacol; 2015 Aug; 27(2):180-4. PubMed ID: 25962818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 5. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on: Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience.
    Kaushik VV; Ambalavanan S; Binymin K
    Rheumatology (Oxford); 2007 Dec; 46(12):1863-4; author reply 1864-5. PubMed ID: 17965441
    [No Abstract]   [Full Text] [Related]  

  • 7. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ; Ranganathan P
    Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
    Ostergaard M; Unkerskov J; Linde L; Krogh NS; Ravn T; Ringsdal VS; Petri A; Andersen LS; Tarp U; Hansen A; Hjardem E; Hetland ML
    Scand J Rheumatol; 2007; 36(2):151-4. PubMed ID: 17476624
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis.
    Radovits BJ; Kievit W; Fransen J; van de Laar MA; Jansen TL; van Riel PL; Laan RF
    Ann Rheum Dis; 2009 Sep; 68(9):1470-3. PubMed ID: 19015210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Aug; 54(8):2701-2. PubMed ID: 16871549
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BSR Biologics Registry.
    Griffiths I; Silman A; Symmons D; Scott DG
    Rheumatology (Oxford); 2004 Dec; 43(12):1463-4. PubMed ID: 15328420
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of pulmonary and cardiac sarcoidosis during etanercept therapy.
    Miyagi R; Ideguchi H; Soga T; Yamakawa Y; Otsuki H; Niino H; Shiina T; Ueda A; Ishigatsubo Y
    Int J Rheum Dis; 2014 Sep; 17(7):810-2. PubMed ID: 24460777
    [No Abstract]   [Full Text] [Related]  

  • 14. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
    Ding T; Ledingham J; Luqmani R; Westlake S; Hyrich K; Lunt M; Kiely P; Bukhari M; Abernethy R; Bosworth A; Ostor A; Gadsby K; McKenna F; Finney D; Dixey J; Deighton C; ;
    Rheumatology (Oxford); 2010 Nov; 49(11):2217-9. PubMed ID: 20837498
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF inhibitors for rheumatoid arthritis - a year in review.
    Simsek I
    Bull NYU Hosp Jt Dis; 2011; 69(3):220-4. PubMed ID: 22035432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcoidosis during etanercept treatment for rheumatoid arthritis in women with a history of bilateral oophorectomy.
    Sawahata M; Sigiyama Y; Yamasawa H; Miki A; Yamamoto H; Muto S; Yamamoto H; Bando M
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Aug; 33(2):178-81. PubMed ID: 27537723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol.
    Langer HE; Missler-Karger B
    Int J Clin Pharmacol Res; 2003; 23(4):119-28. PubMed ID: 15224501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF inhibitors - new and old agents for rheumatoid arthritis.
    Simsek I
    Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.